Replimune GroupFRA:7R8 -3.56%32 ROE % is -156.61% as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,248 Biotechnology companies, Replimune Group ranks worse than 77.96% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Replimune Group's annualized net income for the quarter that ended in Mar. 2026 was €-253.33 Mil. Replimune Group's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €161.76 Mil. Therefore, Replimune Group's annualized ROE % for the quarter that ended in Mar. 2026 was -156.61%.
The historical rank and industry rank for Replimune Group's ROE % or its related term are showing as below:
FRA:7R8'
s ROE % Range Over the Past 10 Years
Min: -112.72 Med: -41.24 Max: -23.7
Current: -112.72
During the past 10 years, Replimune Group's highest ROE % was -23.70%. The lowest was -112.72%. And the median was -41.24%.
FRA:7R8's ROE % is ranked worse than 77.96% of 1248
companies
in the Biotechnology industry
Industry Median: -38.535
vs FRA:7R8: -112.72
Replimune Group (FRA:7R8) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Replimune Group ROE % Related Terms
Replimune Group ROE % Historical Data
* Premium members only.
The historical data trend for Replimune Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Replimune Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's ROE % distribution charts can be found below:
* The bar in red indicates where Replimune Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Replimune Group (FRA:7R8) has a ROE % of -156.61% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #973 out of 1248 companies in the Biotechnology industry, placing it in the top 78%.
Is Replimune Group's ROE % too high?
Replimune Group's current ROE % is -156.61%. Based on the distribution chart, Replimune Group ranks #973 out of 1248 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's ROE % compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #973 out of 1248 companies for ROE %. This places Replimune Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Replimune Group and its competitors. Replimune Group's current ROE % is -156.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current ROE % of -156.61%. The current ROE % is -156.61%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current ROE % is -156.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score
Get the complete analysis for FRA:7R8
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7R8 has been successfully added to your 
